Beyond the Acute Phase: Persistent Pulmonary Findings After COVID-19 in Hungary.

Beyond the Acute Phase: Persistent Pulmonary Findings After COVID-19 in Hungary.

Publication date: Aug 01, 2025

Objective The objective of this one-year study, conducted at KencE9zy Gyula Hospital in Hungary and involving a cohort of 50 hospitalized patients with confirmed SARS-CoV-2 infection, was to assess the long-term impact of the disease on lung morphology. Using follow-up chest CT imaging performed three months post-infection, the study aimed to identify persistent abnormalities such as ground-glass opacities (GGOs), fibrotic-like changes, and other post-inflammatory sequelae. By correlating radiological findings with clinical and laboratory data, the study sought to provide insights into the extent and nature of pulmonary recovery, highlight patterns of incomplete resolution, and contribute to the understanding of potential chronic respiratory consequences of COVID-19. Methods This study included 50 randomly chosen subjects. Those who suffered from COVID-19 and reported to the Emergency Department of the University of Debrecen, Clinical Center KencE9zy Gyula Campus in Hungary were eligible for participation. An initial CT chest with contrast was performed on admission, and a control CT chest with contrast was performed three months following admission. The grading of affected lung parenchyma was subjective (based on the views of experienced radiologists at the department) and not AI-based or computer-guided. For comparison, the percentage of affected lung parenchyma was estimated on both the initial and control CTs. To gain a comprehensive understanding of COVID-19 infections, the subjects’ age, sex, medical history, symptoms on admission, and therapy received were also recorded. Results This study, based on a small sample size of 50 patients aged predominantly between 60 and 75 years, provides insights into the clinical presentation, laboratory findings, imaging features, and treatment approaches for COVID-19. The most common presenting symptoms were fever, cough, and dyspnea, with hypertension, diabetes, and cardiovascular disease being the most frequent comorbidities, factors known to influence disease severity. The most frequent findings on laboratory investigation were lymphopenia, elevated CRP, and D-dimer. This study showed GGOs with or without consolidations to be the hallmark of COVID-19 infection on CT. Regarding therapeutic methods, 74% of subjects received antibiotics (to prevent secondary bacterial infection), 44% received remdesivir, while several others received low-molecular-weight heparin to reduce the likelihood of coagulation. Supportive therapy included theophylline (bronchodilator), acetylcysteine (mucolytic), algopyrin (painkiller), and vitamin C. A great number of patients showed 30-40 (%) affected lung parenchyma on initial CT, while the control CTs depicted 5 (%) affected parenchyma. Conclusion Based on the results of this study, although remarkable recovery from the infection was evident, long-term effects of COVID-19 infection are apparent, with over 40% of patients exhibiting signs of distorted lung architecture. The indicators of fibrosis observed included persistent GGOs, parenchymal bands, septal thickening, and traction bronchiectasis.

Open Access PDF

Concepts Keywords
Ct covid 19
Diabetes covid-19 lung fibrosis
Hungary ct chest
Months lung pathologies
Painkiller sars-cov-2

Semantics

Type Source Name
disease MESH COVID-19
pathway REACTOME SARS-CoV-2 Infection
disease MESH infection
disease MESH abnormalities
disease MESH sequelae
disease MESH Emergency
disease IDO history
disease MESH dyspnea
disease MESH hypertension
disease MESH cardiovascular disease
disease MESH lymphopenia
disease MESH bacterial infection
drug DRUGBANK Theophylline
drug DRUGBANK Acetylcysteine
drug DRUGBANK Ascorbic acid
disease MESH fibrosis
disease MESH bronchiectasis
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
disease IDO host
pathway KEGG Viral replication
disease MESH edema
disease MESH inflammation
disease MESH chronic conditions
disease MESH death
disease MESH pulmonary edema
disease MESH hypoxemia
disease IDO production
disease MESH tachycardia
disease MESH multiple organ dysfunction syndrome
disease MESH anorexia
disease MESH chest pain
disease MESH ageusia
drug DRUGBANK Fibrinogen Human
disease MESH lung injury
drug DRUGBANK Sulodexide
disease MESH clinical relevance
drug DRUGBANK Oxygen
disease MESH morbidity
disease MESH respiratory failure
drug DRUGBANK Tocilizumab
disease MESH syndrome
drug DRUGBANK Lopinavir
drug DRUGBANK Ritonavir
drug DRUGBANK Chloroquine
drug DRUGBANK Hydroxychloroquine
drug DRUGBANK Carbon monoxide
disease MESH asymptomatic infections
drug DRUGBANK Methionine
drug DRUGBANK Aspartame
disease MESH comorbidity
disease MESH COPD
disease MESH joint pain
disease MESH Sore throat
disease MESH Obesity
disease IDO blood
disease IDO immune response
disease MESH leukocytosis
disease MESH Pulmonary embolism
drug DRUGBANK Azithromycin
disease MESH sepsis
drug DRUGBANK Methylprednisolone
disease MESH critical illness
drug DRUGBANK Sulpiride
disease IDO susceptibility
disease MESH asymptomatic disease
disease MESH viral pneumonia
disease MESH causality
disease IDO symptom
disease MESH pneumonitis

Original Article

(Visited 6 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *